PRZOOM - /newswire/ -
Irvine, CA, United States, 2012/08/06 - MDxHealth SA, announced on June 29 the successful capital increase of €10 million through a private placement - MDxHealth.com. NYSE Euronext: MDXH
MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, previously announced on June 29 the successful capital increase of €10 million through a private placement. As a result of this capital increase, the denominator or issued shares with voting rights changed from 18,622, 327 to 25,513, 440. Each shareholder of the Company is entitled to one vote per share.
In addition to the new denominator, there are a total number of 1,562, 116 new shares that could potentially be issued through the exercise of outstanding warrants (vested and non-vested) granted by the Company prior to the private placement.
MDxHealth (mdxhealth.com) is a leading molecular diagnostics company that develops and commercializes epigenetic tests to support cancer treatment. The company’s tests are based on proprietary gene methylation (epigenetics) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy.
For more information:
Mike Sinclair, Halsin Partners
T: +44 20 7318 2955 / C: +44 7968 022075
Important information about forward-looking statements
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of MDxHealth, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale is not permitted or to any person or entity to whom it is unlawful to make such offer, solicitation or sale. This press release is not an offer of securities for sale into the United States, Canada, Australia or Japan. The new shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "US Securities Act") and may not be offered or sold in the United States absent registration or an exemption from registration. The Company does not intend to register any portion of the placing in the United States or to conduct a public offering of securities in the United States.